EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND RESURFACE 2

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Mehta, N. [2 ]
Menter, A. [3 ,4 ]
Mendelsohn, A. M. [5 ]
Rozzo, S. [5 ]
Lebwohl, M. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Baylor Scott & White, Div Dermatol, Dallas, TX USA
[4] Texas A&M Coll Med, Div Dermatol, Dallas, TX USA
[5] Sun Pharmaceut Ind Inc, Med Affairs, Princeton, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1827
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0544
引用
收藏
页码：1304 / 1305
页数：2
相关论文
共 50 条
  • [31] Long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials
    van de Kerkhof, Peter C.
    Dauden, Esteban
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB120 - AB120
  • [32] Long-term Safety of Tildrakizumab: Incidence of undesirable Events of particular Concern during the Treatment of Patients with moderate to severe Psoriasis in the reSURFACE 1 and reSURFACE 2 Studies over 5 Years
    Reich, K.
    Pinter, A.
    Kirsch, A.
    Pau-Charles, I
    Gerdes, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 57 - 58
  • [33] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
    Gooderham, M.
    Papp, K.
    Blauvelt, A.
    Thaci, D.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
  • [34] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
    Tyring, S.
    Spelman, L.
    Igarashi, A.
    Ohtsuki, M.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Guenthner, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
  • [35] Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest
    Egeberg, Alexander
    Jullien, Denis
    Du Jardin, Kristian Gaarn
    Thaci, Diamant
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [36] Severe infections, confirmed extended major adverse cardiovascular events, and malignancies over 5 years of treatment with tildrakizumab in terms of number needed to harm: Pooled analyses from the reSURFACE 1 and reSURFACE 2 phase 3 trials
    Pinter, Andreas
    Lacour, Jean-Philippe
    Egeberg, Alexander
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB108 - AB108
  • [37] Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
    Diamant Thaçi
    Sascha Gerdes
    Kristian Gaarn Du Jardin
    Jean-Luc Perrot
    Lluís Puig
    Dermatology and Therapy, 2022, 12 : 2325 - 2341
  • [38] Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks (vol 182, pg 605, 2020)
    Reich, K.
    Warren, R. B.
    Iversen, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : 131 - 132
  • [39] Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    Reich, Kristian
    Papp, Kim A.
    Blauvelt, Andrew
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Nograles, Kristine
    Mehta, Anish
    Cichanowitz, Nicole
    Li, Qing
    Liu, Kenneth
    La Rosa, Carmen
    Green, Stuart
    Kimball, Alexa B.
    LANCET, 2017, 390 (10091): : 276 - 288
  • [40] Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)
    Igarashi, Atsuyuki
    Nakagawa, Hidemi
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Imafuku, Shinichi
    Tada, Yayoi
    Honma, Masaru
    Mendelsohn, Alan M.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 853 - 863
12345